SESSION DESCRIPTION
Chimeric Antigen Receptor T cell therapies have transformed the outcomes of patients with relapsed and refractory multiple myeloma and its role continues to expand at a rapid pace. This session brings together cutting edge data spanning novel approaches to improve the safety and efficacy of CAR-T products in the clinic. Presenters will explore how new strategies are changing the efficacy and safety balance to reshape treatment paradigms as the field pushes towards deeper and more durable responses. Attendees will get insights into latest clinical data in this important session.
KEYWORDS
Treatment Considerations, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult